Literature DB >> 12742626

Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease.

Mitchell K P Lai1, Shirley W Y Tsang, Paul T Francis, Margaret M Esiri, Janet Keene, Tony Hope, Christopher P L-H Chen.   

Abstract

Previous studies have implicated brain serotonin 5-HT(1A) receptors in several CNS functions, including cognition, mood and emotional states. In Alzheimer disease (AD), cognitive impairment and behavioral symptoms are the main clinical features. However, the biochemical basis of such changes is poorly understood. Results from recent in vivo studies suggest that 5-HT(1A) receptors may be related to aggressive traits in healthy subjects. The present study investigated the state of 5-HT(1A) receptors in the postmortem neocortex of 33 AD patients prospectively assessed for cognition and behavioral symptoms, together with 20 matched controls, by saturation [(3)H]8-OH-DPAT binding assays. 5-HT(1A) receptor binding affinity (K(D)) and density (B(max)) were unchanged in the overall AD group compared with controls. Within the AD group, 5-HT(1A) receptor B(max) in the temporal cortex inversely correlated with aggression and dementia severity. However, multiple regression analyses showed that 5-HT(1A) receptor B(max) remained the best predictor for aggression, while temporal cortical neurofibrillary tangle grading was the best predictor for dementia severity. This suggests that 5-HT(1A) receptor alteration is directly related to aggression in AD, while dementia severity is more strongly related to the neurodegenerative process. Our data indicate further study of 5-HT(1A) receptors as a pharmacological target for the treatment of behavioral symptoms in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742626     DOI: 10.1016/s0006-8993(03)02554-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  46 in total

Review 1.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

2.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 3.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 4.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

5.  Can dietary intervention help in management of problem behaviors in dementia?

Authors:  L Volicer
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

6.  An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Masanori Ishikawa; Hiroyasu Akatsu; Eric E Abrahamson; Milos D Ikonomovic; Takashi Asada
Journal:  Neuropathology       Date:  2011-01-27       Impact factor: 1.906

7.  Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.

Authors:  Mitchell K P Lai; Shirley W Tsang; Margaret M Esiri; Paul T Francis; Peter T-H Wong; Christopher P Chen
Journal:  Psychopharmacology (Berl)       Date:  2010-07-13       Impact factor: 4.530

Review 8.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 9.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

10.  Disruptive behavior as a predictor in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Deborah Blacker; Marilyn Albert; Georgios Hadjigeorgiou; Bruno Dubois; Davangere Devanand; Lawrence Honig; Yaakov Stern
Journal:  Arch Neurol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.